Takeda at a glance | Takeda 2025 Annual Integrated Report
Takeda at a glance
We’re a global biopharmaceutical company – patient-focused, values-based and driven by innovative research and development. We’ve been in the business of improving people’s health for more than 240 years.
We have a value chain model based on three main activities:
- R&D: our aim is to discover and develop life-transforming medicines for patients with both rare and more prevalent diseases.
- Manufacturing & supply: we have 22 sites worldwide, manufacturing our medicines and vaccines.
- Bringing our medicines to patients: throughout our operations, we always put patients first – that includes our commercial strategy.
Data, digital and technology (DD&T) is embedded in all that we do to advance our pipeline with improved speed and quality.
Underpinning our strategy are our Growth & Launch Products. We expect these products to provide strong sales momentum in future years. These products are also testimony to Takeda’s continued commitment to patient-centered innovation. They include ENTYVIO®, our treatment for ulcerative colitis and Crohn’s disease, as well as QDENGA®, our dengue fever vaccine and FRUZAQLA®, used in the treatment of metastatic colorectal cancer.
Revenue by focus area
Revenue by country and region
Our FY2024 financial performance highlights
Learn more about our six focus areas
Sign up for our investors newsletter
Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet.
Sign up